Related Experiment Video
Updated: Mar 14, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks
Mandeep Singh1, Deepak L Bhatt2, Gregg W Stone3
1Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Insights
Managing acute coronary syndrome (ACS) requires balancing antithrombotic therapies to reduce ischemia without increasing bleeding. This review guides healthcare providers in individualizing treatment for better patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndrome (ACS) affects 620,000 individuals annually in the US, with 70% experiencing non-ST-elevation ACS.
- Cardiovascular disease remains a leading cause of death, necessitating improved ACS patient prognosis.
- While newer antithrombotic therapies reduce ischemic events, they increase bleeding risk, complicating treatment decisions.
Purpose of the Study:
- To synthesize current knowledge on antithrombotic therapy for acute coronary syndrome.
- To provide healthcare providers with evidence-based information for individualizing treatment decisions.
- To address the challenge of selecting antithrombotic combinations that minimize recurrent ischemia and bleeding.
Main Methods:
- Review of contemporary antithrombotic therapies for acute coronary syndrome.
- Synthesis of data on balancing ischemic versus bleeding risks.
- Analysis of therapeutic strategies for non-ST-elevation acute coronary syndrome.
Main Results:
- Newer antithrombotic agents offer benefits but increase bleeding complications.
- Individual patient risk for ischemia and hemorrhage must guide therapeutic choices.
- Optimal antithrombotic strategies require careful consideration of patient-specific factors.
Conclusions:
- Personalized antithrombotic therapy is crucial for managing acute coronary syndrome.
- Balancing antithrombotic efficacy and safety is key to improving patient prognosis.
- Healthcare providers need updated knowledge to navigate complex treatment decisions in ACS.
Abstract:
It is estimated that in the United States, each year, approximately 620,000 persons will experience an acute coronary syndrome and approximately 70% of these will have non-ST-elevation acute coronary syndrome. Cardiovascular disease still accounts for 1 of every 3 deaths in the United States, and there is an urgent need to improve the prognosis of patients presenting with acute coronary syndrome. Cardiovascular mortality and ischemic complications are common after acute coronary syndrome, and the advent of newer antithrombotic therapies has reduced ischemic complications, but at the expense of greater bleeding. The new antithrombotic agents also raise the challenge of choosing between multiple potential therapeutic combinations to minimize recurrent ischemia without a concomitant increase in bleeding, a decision that often varies according to an individual patient's relative propensity for ischemia versus hemorrhage. In this review, we will synthesize the available information to arm health care providers with the contemporary knowledge on antithrombotic therapy and individualize treatment decisions.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care